Wrist access heart procedure gets a boost from nitroglycerin shot
NCT ID NCT03304496
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a small shot of nitroglycerin under the skin can widen the wrist artery, making it easier for doctors to insert a tube for heart procedures. It involves 1,400 adults with coronary artery disease scheduled for heart catheterization. The goal is to reduce the need to switch to leg access and lower complications like bruising or bleeding.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 1,400 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2018
- Expected to finish
-
Mar 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Men and women older than 18 years, scheduled consecutively to perform a coronary procedure in the department of hemodynamics of the National Institute of Cardiology "Ignacio Chavez". * Patients may have any of the following indications for cardiac catheterization: Thoracic pain under study. Stable chronic coronary disease. Acute myocardial infarction with ST segment elevation, not perfused (without timely reperfusion therapy) with less than 4 weeks of evolution. Acute myocardial infarction with ST-segment elevation, successful thrombolytic therapy, which will undergo drug-invasive therapy. Acute myocardial infarction without ST segment elevation. Unstable angina. Any acute coronary syndrome, to intervene non-infarct-related artery. Disease of any heart valve. Myocarditis or pericarditis. Dilated cardiomyopathy. Patients in renal or cardiac transplantation protocol for any etiology. Congenital heart disease that requires knowing the coronary anatomy prior to surgical correction. * The planned procedure can be any of the following: For diagnostic purposes (coronary angiography only, left catheterization, left and right catheterization). For therapeutic purposes: percutaneous coronary intervention (PCI), with or without stent placement. * A priori access must be right or left radial artery. * Radial arterial pulse may be present or absent by palpation. * Modified Allen or Barbeau test should be positive (presence of collateral palmar flow). Exclusion Criteria: * Pregnant. * Not have informed consent for the present clinical trial, or do not fully understand the meaning of informed consent. * With acute myocardial infarction with ST segment elevation in the first 12 hours from the onset of symptoms. * With any acute coronary syndrome complicated with acute pulmonary edema, cardiogenic shock and / or malignant ventricular arrhythmias. * In which a cardiac catheterization is planned a priori to be performed via femoral, brachial or ulnar. * Patients in whom first attempt of arterial puncture is performed by 2nd year interventional cardiology fellow or by physician in charge. * Participating in another clinical trial. * Be allergic or have contraindications to nitroglycerin or other nitrates. * Any phosphodiesterase 5 inhibitor (sildenafil, tadalafil, avanafil, vardenafil) has been taken within 72 hours prior to the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Instituto Nacional de Cardiologia Ignacio Chavez
Mexico City, Tlalpan, 04480, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- SMART-I: SiroMax™ Multi-Center coronary artery lesion treatment - safety and feasibility study of SiroMax SCB in ISR and DNSV
- Hospital-to-Home transitional cardiac rehabilitation as a transition from Centre-Based cardiac rehabilitation after cardiac surgery: a Single-Blind randomised controlled trial
- Opportunistic screening of coronary artery calcium on Non-Gated routine chest CT using artificial intelligence: retrospective external validation and clinical risk stratification
- AI heart scan software aims to spot dangerous blockages without invasive probes
- A shot of nicorandil before stenting might keep blood flowing
- Can personalized breathing settings protect lungs during heart surgery?